Loading organizations...
Loading organizations...
PolyRemedy is a technology company.
PolyRemedy develops integrated wound management systems to enhance clinical care. Its core offerings include the HealSmart Software Platform, providing web-based assessment tools and real-time feedback, alongside personalized antimicrobial wound dressings. The company's technical approach leverages advanced wound-healing technology, incorporating robotics and nanotechnology, to deliver tailored protocols at the point of care.
Dr. Oleg Siniaguine founded PolyRemedy in 2004, driven by the insight to develop proprietary wound-healing technology for consistent, expert patient care. His background supported establishing a firm dedicated to innovating medical solutions in wound management, aiming to embed specialized expertise directly into its product suite.
PolyRemedy serves home health agencies, equipping them with tools that improve efficiency and patient outcomes. The company’s vision centers on extending advanced wound care knowledge and capabilities into diverse settings, enabling clinicians to document progress, make informed decisions, and enhance patient recovery with crucial visibility into wound care data.
PolyRemedy has raised $62.4M across 7 funding rounds.
PolyRemedy has raised $62.4M in total across 7 funding rounds.
PolyRemedy is a medtech company developing robotic systems for personalized wound care, using nanotechnology to create custom dressings at the point of care.[1][2][3] It serves healthcare providers like clinicians and hospitals, solving inconsistent wound treatment by delivering evidence-based, tailored therapeutics that improve healing outcomes through integrated IT and robotics.[2][3][4] The company raised $25 million in Series B funding in 2011, co-led by Advanced Technology Ventures and IDG Ventures Boston, signaling strong growth momentum in advanced wound management.[1]
PolyRemedy emerged from the need to extend wound care expertise directly to clinicians via technology, founded prior to its 2011 Series B round in Mountain View, California.[1][5] While specific founders are not detailed in available records, the company quickly gained traction with investments from MedVenture Associates (Series A) and new backers like Harris & Harris Group, culminating in the $25 million raise to scale its robotic nano-material delivery platform.[1] A pivotal moment was securing FDA clearance for antimicrobial dressings, enhancing its personalized woundcare system.[4]
PolyRemedy rides the wave of precision medtech and personalized healthcare, where robotics and nanotech address chronic wounds—a market strained by aging populations and rising diabetes cases.[1][2] Timing aligns with post-2010 advances in point-of-care automation, enabling scalable expert care amid clinician shortages.[3][4] Favorable forces include FDA support for innovative dressings and VC interest in health IT convergence, positioning PolyRemedy to influence wound management standards by standardizing personalized treatments.[1][4][5]
PolyRemedy is poised to expand its robotic platform amid growing demand for automated, data-driven wound care, potentially targeting larger hospital networks and global markets.[1][2] Trends like AI-enhanced diagnostics and nanotech scalability will shape its path, evolving its influence from niche innovator to ecosystem leader in chronic care. This builds on its funding-fueled momentum, promising broader impact in consistent, point-of-care healing.[1][4]
PolyRemedy has raised $62.4M in total across 7 funding rounds.
PolyRemedy's investors include Aisling Capital, Flagship Pioneering, Flare Capital Partners, Johnson & Johnson Innovation, Polaris Partners, Delphi Ventures, Advanced Technology Ventures, Flybridge Capital Partners, MedVenture Associates.
PolyRemedy has raised $62.4M across 7 funding rounds. Most recently, it raised $880K Venture Round in April 2016.